Very interesting discovery Titus!
Yes, sells Inhibitex to BMS for US$2.5billion, largely on the back of INX-189 HepC antiviral which BMS subsequently rename BMS-986094 and which is held responsible for a patient fatality, resulting in the discontinuation of the drug's development.
Reads like a scene from a movie.
Is this guy really JR Ewing in disguise??
Possibly a little more research required here.
proposed new ceo is, page-11
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)